Medical Pharmacology Question Bank
Chapter: Sedative-Hypnotic Drugs — Chapter 12 — Module: Module 4 — Toxicology, Dependence & Clinical Management
Tier: T3 — Clinical Vignette (11 questions)
1. A 34-year-old man is brought to the emergency department after ingesting an unknown quantity of phenobarbital tablets approximately 90 minutes ago. He is obtunded but protecting his airway. Vital signs: BP 98/62 mmHg, HR 58 bpm, RR 10 breaths/min, temperature 35.8°C. Activated charcoal has been given. The toxicology team recommends continuing activated charcoal doses every 4–6 hours. Which of the following best explains the pharmacological rationale for multi-dose activated charcoal (MDAC) in phenobarbital toxicity?
ANSWER: C
Rationale:
Phenobarbital undergoes significant enterohepatic recirculation — after hepatic conjugation, it is secreted into bile and then reabsorbed in the small intestine, returning to systemic circulation. Multi-dose activated charcoal (MDAC) — repeated doses of activated charcoal (25–50 g every 4–6 hours) — exploits two complementary mechanisms to enhance phenobarbital elimination: it interrupts this enterohepatic recirculation cycle by adsorbing biliary-excreted phenobarbital in the intestinal lumen before it can be reabsorbed, and it acts as a gastrointestinal dialysis sink — because activated charcoal maintains a very low intraluminal drug concentration, phenobarbital passively diffuses from the mesenteric capillary blood back into the gut lumen along the concentration gradient, where it is adsorbed and eliminated in stool. This makes MDAC one of the clearest and best-supported indications in clinical toxicology, capable of meaningfully shortening the elimination half-life of phenobarbital.
2. A 28-year-old woman is brought to the emergency department by EMS after being found unresponsive at home. Her roommate reports she has been taking clonazepam prescribed for panic disorder for the past two years and takes it daily. Empty bottles of clonazepam and a tricyclic antidepressant (TCA) are found at the scene. On arrival she is unresponsive with a GCS of 6, RR 8 breaths/min, BP 84/52 mmHg, and QRS duration 138 ms on the cardiac monitor. The emergency physician considers administering flumazenil for benzodiazepine (BZD) reversal. Which of the following best explains why flumazenil is contraindicated in this patient?
ANSWER: A
Rationale:
Flumazenil is a competitive GABA-A receptor antagonist that reverses benzodiazepine-mediated sedation but carries two well-established contraindications that are both present here. First, chronic benzodiazepine dependence: in a patient taking clonazepam daily for two years, GABA-A receptors have undergone compensatory downregulation and the patient is physically dependent; abrupt receptor blockade by flumazenil precipitates acute benzodiazepine withdrawal, manifesting as seizures — a potentially life-threatening complication that would compound an already critical presentation. Second, TCA co-ingestion: tricyclic antidepressants (TCAs) are potently proconvulsant through sodium channel blockade and anticholinergic mechanisms; the widened QRS (138 ms) confirms significant TCA toxicity here. Benzodiazepines provide some degree of inhibitory buffering against TCA-driven seizures; flumazenil-mediated removal of this GABA-A tone in the setting of TCA toxicity markedly increases seizure risk. The combination of dependence and TCA co-ingestion makes flumazenil strongly contraindicated.
3. A 52-year-old man with known obstructive sleep apnea (OSA) undergoes a colonoscopy under moderate procedural sedation with midazolam and fentanyl. He is receiving supplemental oxygen at 4 L/min via nasal cannula throughout the procedure. Fifteen minutes into the procedure, his pulse oximetry reads SpO2 98%. The anesthesiologist notes that capnography shows end-tidal CO2 (ETCO2) rising from 38 to 61 mmHg over the preceding 8 minutes. Which of the following best explains the clinical significance of this capnography finding in a patient receiving supplemental oxygen?
ANSWER: E
Rationale:
This scenario illustrates a critical limitation of pulse oximetry in patients receiving supplemental oxygen. SpO2 reflects oxygen saturation of hemoglobin; when supplemental oxygen is administered, the oxygen reservoir in the alveoli and blood is sufficient to maintain normal SpO2 even as ventilation decreases significantly and CO2 accumulates. A patient can be meaningfully hypoventilating — with rising PaCO2 and impending respiratory failure — while SpO2 remains reassuringly normal. Capnography (end-tidal CO2 monitoring), by measuring the CO2 concentration in exhaled breath, detects hypoventilation in real time, well before oximetry deteriorates. The rise from 38 to 61 mmHg ETCO2 here indicates worsening hypoventilation requiring immediate intervention — stimulation, jaw thrust, or reduction of sedation depth — despite the normal SpO2. This gap between capnography warning and oximetry deterioration is substantially widened in patients on supplemental oxygen, in patients with obesity or obstructive sleep apnea (OSA), and in those receiving opioids that blunt the hypercapnic ventilatory response. For this reason, capnography is required or strongly recommended for deep procedural sedation and is increasingly standard for moderate sedation as well.
4. A 61-year-old man with a 30-year history of heavy alcohol use is admitted for alcohol withdrawal management. He is alert and cooperative. His Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) score on admission is 14. The medical team initiates a symptom-triggered benzodiazepine protocol, administering lorazepam only when CIWA-Ar scores exceed 10, rather than a fixed-schedule every-4-hour dosing regimen. Compared to fixed-schedule dosing, which of the following outcomes has been most consistently demonstrated with symptom-triggered dosing in randomized trials of patients capable of cooperating with CIWA-Ar assessment?
ANSWER: B
Rationale:
Multiple randomized controlled trials have demonstrated that symptom-triggered dosing — administering benzodiazepines only when CIWA-Ar scores exceed a defined threshold (typically 8–10) — reduces total benzodiazepine consumption by approximately 60–70% and significantly shortens treatment duration compared to fixed-schedule dosing (e.g., lorazepam every 4–6 hours regardless of symptoms), without increasing the rate of withdrawal seizures or delirium tremens (DT) in patients who can cooperate with CIWA-Ar assessment. The mechanism is straightforward: fixed-schedule dosing administers drug whether or not the patient is experiencing significant withdrawal symptoms, leading to excess sedation and drug accumulation in patients whose withdrawal course is mild or moderate. Symptom-triggered dosing titrates drug to actual withdrawal severity, avoiding unnecessary exposure. The key qualification — "patients who can cooperate with CIWA-Ar scoring" — is clinically important: CIWA-Ar requires patient participation in assessment (orientation questions, reporting subjective symptoms), and the protocol is not validated in patients with significant cognitive impairment, encephalopathy, or psychiatric conditions that preclude reliable scoring.
5. A 47-year-old woman with severe alcohol use disorder is brought to the emergency department in moderate-to-severe alcohol withdrawal. Her Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) score is 22. She has received 40 mg of diazepam over the past 3 hours with minimal response — she remains tremulous, diaphoretic, and increasingly agitated. The critical care team prepares phenobarbital loading. Which of the following best explains the mechanistic advantage of phenobarbital over benzodiazepines in severe alcohol withdrawal syndrome (AWS) refractory to benzodiazepines?
ANSWER: D
Rationale:
Chronic alcohol use produces compensatory neuroadaptation at GABA-A receptors (downregulation, internalization, reduced sensitivity) and NMDA glutamate receptors (upregulation, increased excitatory tone). In severe withdrawal, this combined inhibitory deficit and excitatory excess can overwhelm benzodiazepine therapy because benzodiazepines require endogenous GABA to be present and functional — they are positive allosteric modulators that enhance GABA's effect, but cannot substitute for it. When GABA-A receptors are severely downregulated, benzodiazepines lose efficacy. Phenobarbital overcomes this limitation through two mechanistic advantages: (1) at the concentrations achieved by loading doses (10–15 mg/kg IV), phenobarbital directly activates GABA-A chloride channels independently of GABA — it functions as a direct channel agonist, not merely a potentiator, bypassing the receptor downregulation that limits benzodiazepine efficacy; and (2) phenobarbital inhibits AMPA-type glutamate receptors, directly attenuating the excitatory hyperactivity that is the other limb of withdrawal pathophysiology. Additionally, phenobarbital's long half-life (80–120 hours) provides sustained withdrawal coverage without pharmacokinetic instability.
6. A 44-year-old man presents requesting help tapering off alprazolam 2 mg three times daily, which he has taken for generalized anxiety disorder for six years. His physician plans to convert him to an equivalent dose of diazepam before initiating a structured taper. Using a conservative equivalency of 0.25 mg alprazolam per 5 mg diazepam, what is the approximate total daily diazepam equivalent for this patient's current alprazolam regimen, and why is the conservative estimate preferred over the 0.5 mg alprazolam per 5 mg diazepam ratio in initiating the taper?
ANSWER: C
Rationale:
The patient is taking alprazolam 2 mg three times daily, for a total daily dose of 6 mg. Using the conservative equivalency of 0.25 mg alprazolam per 5 mg diazepam, the conversion is: 6 mg alprazolam ÷ 0.25 mg per 5 mg diazepam unit = 24 units × 5 mg = 120 mg diazepam daily. The conservative 0.25 mg ratio (rather than the 0.5 mg ratio sometimes cited) is specifically recommended when initiating the taper in high-dose, long-term alprazolam users because alprazolam is a high-potency, short-acting benzodiazepine with rapid receptor binding kinetics — properties that are associated with deeper physical dependence relative to the milligram dose, compared to lower-potency, longer-acting agents. Using the 0.5 mg ratio (which would yield only 60 mg diazepam daily in this patient) risks under-substitution — insufficient diazepam to fully suppress the withdrawal syndrome — which can precipitate acute withdrawal at the very outset of the taper. The more conservative ratio errs toward adequate suppression of the dependence state before reduction begins.
7. A 39-year-old woman with no prior psychiatric history presents to her primary care physician after a motor vehicle accident three months ago in which she was uninjured but witnessed severe trauma. She was prescribed lorazepam 0.5 mg twice daily for acute anxiety at that time and has taken it continuously since. She now asks why benzodiazepines treat alcohol withdrawal, since she thought alcohol and benzodiazepines were "different drugs." The physician explains the pharmacological concept of cross-dependence. Which of the following best explains the mechanistic basis for benzodiazepine efficacy in alcohol withdrawal syndrome?
ANSWER: A
Rationale:
Cross-dependence between alcohol and benzodiazepines arises because both drug classes produce their primary CNS depressant effects through positive modulation of GABA-A receptors — alcohol enhances GABA-A chloride conductance through binding at distinct sites on the receptor complex (including transmembrane and extracellular sites), and benzodiazepines potentiate GABA's effect at the benzodiazepine allosteric site. Chronic exposure to either agent produces the same compensatory receptor-level neuroadaptation: GABA-A receptor downregulation (reduced surface expression, altered subunit composition, reduced chloride conductance) and reciprocal upregulation of excitatory NMDA glutamate receptors. When alcohol is abruptly withdrawn, this pre-existing imbalance — reduced inhibitory GABA-A tone and enhanced excitatory glutamate tone — is unmasked, producing the alcohol withdrawal syndrome. Because benzodiazepines act on the identical GABA-A receptor system that has undergone these neuroadaptations, they can restore adequate inhibitory tone and suppress the withdrawal syndrome, regardless of which GABA-A-active agent was the original cause. This is the pharmacological definition of cross-dependence: shared receptor-level neuroadaptation conferring mutual suppression of withdrawal symptoms.
8. A 58-year-old man with acute respiratory distress syndrome (ARDS) is mechanically ventilated in the medical intensive care unit (ICU). He is currently receiving a continuous midazolam infusion at 5 mg/hour, titrated to a Richmond Agitation-Sedation Scale (RASS) score of −4 (deep sedation). His attending physician reviews the current Society of Critical Care Medicine PADIS (Pain, Agitation/Sedation, Delirium, Immobility, Sleep) guidelines and recommends transitioning to a lighter sedation strategy. Which of the following sedation targets and agent choices is most consistent with current PADIS guideline recommendations for mechanically ventilated ICU patients who do not require deep sedation for clinical reasons?
ANSWER: E
Rationale:
The PADIS guidelines from the Society of Critical Care Medicine represent the current evidence-based standard for ICU sedation and explicitly endorse several interconnected components that together define the preferred sedation strategy for most mechanically ventilated patients. Analgesia-first sedation: treat pain before adding sedatives, since pain is a major driver of agitation and unrecognized pain often underlies apparent sedation inadequacy. Light sedation target: a RASS score of 0 to −2 (alert-to-lightly sedated) is the recommended default target for most mechanically ventilated patients, as deep sedation (RASS −3 to −5) is independently associated with prolonged mechanical ventilation, ICU-acquired weakness, cognitive impairment, and post-traumatic stress disorder. Benzodiazepine avoidance: benzodiazepine infusions (particularly midazolam) are associated with prolonged mechanical ventilation and increased delirium compared to propofol and dexmedetomidine, and the PADIS guidelines recommend avoiding benzodiazepine infusions as routine ICU sedation in preference for propofol or dexmedetomidine. Daily SATs combined with SBTs: the combination of daily spontaneous awakening trials (SATs — cessation of sedation) with daily spontaneous breathing trials (SBTs — assessment of readiness to wean from ventilator support) is associated with significantly reduced ventilator days and ICU length of stay.
9. A 52-year-old woman has been taking diazepam 20 mg daily for insomnia and anxiety for eight years. Her psychiatrist initiates a structured taper and converts her to an equivalent diazepam dose before beginning the reduction. She asks how long the taper will take and at what rate. Her psychiatrist explains the evidence-based taper rate. Which of the following best describes the recommended rate of reduction and the rationale for slowing the taper as the dose decreases?
ANSWER: B
Rationale:
Evidence from randomized controlled trials and systematic reviews supports a taper rate of no faster than 5–10% of the current dose per week as the standard starting framework for benzodiazepine discontinuation. Critically, the recommendation to slow the taper further — to 5% or less per 2 weeks — as the dose decreases reflects an important pharmacodynamic principle: the relationship between benzodiazepine dose and receptor occupancy is not linear across the full dose range. At higher doses, a 10% reduction represents a relatively small proportional change in receptor occupancy because the dose-occupancy curve is in a range where large dose changes produce modest occupancy changes. As the dose falls toward lower levels, the same percentage reduction now represents a larger proportional change in receptor occupancy, making withdrawal symptoms more likely and more severe if the rate is not reduced. The "Ashton manual" framework — converting to diazepam and reducing by approximately 0.5–2 mg diazepam equivalents every 2 weeks — is widely used clinically as a practical starting point, with the expectation of taper duration of months to years for patients on long-term high-dose therapy.
10. A 26-year-old woman delivers a full-term infant at 38 weeks gestation. She had been taking clonazepam 1 mg twice daily throughout her third trimester for a panic disorder managed in consultation with psychiatry. Forty-eight hours after birth, the neonatal team notes the infant has developed irritability, high-pitched crying, tremulousness, feeding difficulties, and poor sleep consolidation. The neonatologist diagnoses neonatal abstinence syndrome (NAS) related to in-utero benzodiazepine exposure and determines that pharmacological treatment is required. Which of the following is the agent of choice for pharmacological management of benzodiazepine-associated neonatal abstinence syndrome (BZD-NAS)?
ANSWER: D
Rationale:
Benzodiazepine-associated neonatal abstinence syndrome (BZD-NAS) arises because chronic in-utero benzodiazepine exposure produces GABA-A receptor downregulation and compensatory upregulation of excitatory pathways in the fetal CNS — the same receptor-level neuroadaptation seen in adult benzodiazepine dependence. When placental drug transfer ceases at delivery, the resulting neurological hyperexcitability manifests as the withdrawal syndrome. Phenobarbital is the agent of choice for pharmacological management of BZD-NAS for two mechanistic reasons that directly address this pathophysiology: first, phenobarbital directly activates GABA-A chloride channels independently of GABA at therapeutic neonatal concentrations, restoring inhibitory tone even in the setting of receptor downregulation without relying on the downregulated receptors as positive allosteric targets; second, phenobarbital's very long half-life (80–120 hours in adults; prolonged further in neonates due to immature hepatic metabolism) provides gradual self-tapering pharmacokinetic coverage that smoothly resolves the withdrawal syndrome without requiring a complex dosing schedule.
11. A 55-year-old man has been taking temazepam 30 mg nightly for insomnia for four years, prescribed and monitored by his internist. He has never escalated his dose beyond the prescribed amount, has not sought early refills, has not used the medication for any purpose other than sleep, and has no history of alcohol or other substance use. His internist notes that he has developed pharmacological tolerance — requiring the same dose to achieve less effect than initially — and that he experiences rebound insomnia and mild anxiety when he misses doses. The patient asks whether he has "a drug addiction." Which of the following best characterizes this patient's clinical status according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria?
ANSWER: C
Rationale:
This is a clinically critical distinction that is frequently misunderstood by patients and occasionally by clinicians. The DSM-5 categorizes problematic benzodiazepine use under Sedative, Hypnotic, or Anxiolytic Use Disorder, defined as a problematic pattern of use leading to clinically significant impairment or distress, manifested by two or more of eleven criteria within a 12-month period. The eleven criteria span four domains: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal). Crucially, the DSM-5 explicitly states that tolerance and withdrawal do not count toward the use disorder diagnosis when they occur solely in the context of medically supervised therapeutic use and in the absence of the other criteria. This exception is clinically essential: physical dependence — the neurobiological adaptation to a chronically administered drug, manifested as tolerance and withdrawal — is an expected and predictable pharmacological consequence of regular benzodiazepine use, distinct from addiction or use disorder. This patient displays no behavioral criteria: no loss of control over use, no escalation beyond prescribed doses, no continued use despite harm, no impairment of role function, no craving, no time spent obtaining or recovering from the drug beyond normal prescription use. Without at least two qualifying criteria (and with the pharmacological criteria excluded in this supervised context), the use disorder diagnosis is not met. Failure to explain this distinction clearly to patients can damage therapeutic relationships and create barriers to appropriate prescribing.